Who
Brian C. Stephenson
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Faeth Therapeutics; CFO and Treasurer, BridgeBio Pharma.
In numbers
- Trades disclosed
- 213
- Buys
- 9
- Sells
- 30
- Bought
- $3.7M
- Sold
- $11.3M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Jul 2019
- Last trade
- 1 Jul 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $103K4,400 at $23.40 | filing |
| 1 Jul 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K600 at $24.22 | filing |
| 1 Jul 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $103K4,400 at $23.40 | filing |
| 1 Jul 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K600 at $24.22 | filing |
| 30 Jun 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $44K1,910 at $22.95 | filing |
| 30 Jun 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $39K1,638 at $23.88 | filing |
| 30 Jun 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $106K4,255 at $24.98 | filing |
| 30 Jun 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $44K1,910 at $22.95 | filing |
| 30 Jun 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $39K1,638 at $23.88 | filing |
| 30 Jun 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $106K4,255 at $24.98 | filing |
| 29 Jun 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K831 at $23.34 | filing |
| 29 Jun 2026filed 1 Jul 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K831 at $23.34 | filing |
| 26 Jun 2026filed 26 Jun 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K580 at $23.61 | filing |
| 26 Jun 2026filed 26 Jun 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $105K4,212 at $24.90 | filing |
| 26 Jun 2026filed 26 Jun 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $35K1,358 at $25.55 | filing |
| 26 Jun 2026filed 26 Jun 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,639100 at $26.39 | filing |
| 26 Jun 2026filed 26 Jun 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K580 at $23.61 | filing |
| 26 Jun 2026filed 26 Jun 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $105K4,212 at $24.90 | filing |
| 26 Jun 2026filed 26 Jun 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $35K1,358 at $25.55 | filing |
| 26 Jun 2026filed 26 Jun 2026 | FTH Faeth TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,639100 at $26.39 | filing |
News
Faeth Therapeutics: Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against GedatolisibFTH · finanznachrichten.de · 23 Oct 2026Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 7% – Should You Sell?FTH · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Brian C. Stephenson; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.